REPRIEVE (A5332) is a large double-blind, randomized, placebo-controlled study of pitavastatin or placebo for about 72 months....
The purpose of this study is to evaluate the safety, tolerability, and effect of an experimental human monoclonal antibody...
1077FF is a randomized strategy trial, which is part of the PROMISE studies (1077BF, 1077FF, P1084s, and 1077HS). The Promoting...
An estimated 3 million HIV-infected individuals will enter programs for antiretroviral (ARV) treatment in the coming year, with...
A major disadvantage of giving SD NVP is the potential for maternal development of NVP resistance and additional resistance to...
